From an immunometabolic perspective, serum levels of interleukin-13 (IL-13), interleukin-10 (IL-10), and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) are increased in SSc patients and these molecules have been proposed to exert a protective effect against T2D [42–45]. Here, IL13 is linked to systemic sclerosis.